Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated